Since the FDA approved Ipilimumab which is a human CTLA-4 blocking antibody and alters the adaptive immune system (Carreau and Pavlick, 2019) for the treatment of melanoma in 2011, cancer immunotherapy has become an epoch-making achievement and has achieved some exciting clinical applications. Here, CTLA4 is linked to cancer.